SIGHT — Gensight Biologics SA Balance Sheet
0.000.00%
- €33.81m
- €50.46m
- €1.50m
Annual balance sheet for Gensight Biologics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 37.9 | 44.3 | 10.6 | 2.13 | 2.46 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 3.91 | 4.63 | 3.63 | 2.44 | 2 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 43.8 | 53.4 | 22.9 | 6.53 | 5.34 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.15 | 2.55 | 2.27 | 2.02 | 0.933 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 47.4 | 56.6 | 25.9 | 9.13 | 10.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17.1 | 22.2 | 14.6 | 25.3 | 22.6 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 35.6 | 40.7 | 41.2 | 39.8 | 37.7 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 11.7 | 16 | -15.3 | -30.7 | -26.9 |
Total Liabilities & Shareholders' Equity | 47.4 | 56.6 | 25.9 | 9.13 | 10.8 |
Total Common Shares Outstanding |